Oxygen Biotherapeutics Announces It Will Present at the 15th Annual BIO CEO & Investor Conference on February 11

  Oxygen Biotherapeutics Announces It Will Present at the 15th Annual BIO CEO
  & Investor Conference on February 11

BIO CEO & Investor Conference 2013

Business Wire

MORRISVILLE, N.C. -- January 30, 2013

Oxygen Biotherapeutics, Inc. ("Oxygen") (NASDAQ:OXBT) announced today the
Company will be presenting at the 15^th Annual BIO CEO & Investor Conference
to be held at the Waldorf Astoria Hotel in New York City, February 11-12.
Michael Jebsen, President and Chief Financial Officer of Oxygen, will present
a corporate overview and update on Monday, February 11 at 9 am EST. The
presentation will be webcast live and can be accessed on the company’s web
site or by clicking on the following link
http://www.veracast.com/webcasts/bio/ceoinvestor2013/12102288.cfm. A replay
will be made available for a limited time online on the company’s web site.

The conference, organized by the Biotechnology Industry Organization, is
designed to offer participating companies networking opportunities to build
awareness, establish partnerships and to attract investors. For more
information on the conference, click here.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is developing medical products that efficiently
deliver oxygen to tissues in the body. The company has developed a proprietary
perfluorocarbon (PFC) therapeutic oxygen carrier called Oxycyte^® that is
currently in clinical and preclinical studies for intravenous delivery for
indications such as traumatic brain injury, decompression sickness and stroke.
The company has also developed PFC-based creams and gels for topical delivery
to the skin potentially for wound care and dermatologic conditions.

Caution Regarding Forward-Looking Statements

This news release contains certain forward-looking statements by the company
that involve risks and uncertainties and reflect the company's judgment as of
the date of this release. The forward-looking statements are subject to a
number of risks and uncertainties including matters beyond the company's
control that could lead to delays in new product introductions and customer
acceptance of these new products, and other risks and uncertainties as
described in our filings with the Securities and Exchange Commission,
including in the current Form 10-Q filed on December 14, 2012, and our annual
report on Form 10-K filed on July 24, 2012, as well as other filings with the
SEC. The company disclaims any intent or obligation to update these
forward-looking statements beyond the date of this release. This caution is
made under the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995.


Oxygen Biotherapeutics, Inc.
Ellen Corliss, 919-855-2112
Senior Vice President,
Corporate Communications & Investor Relations
Press spacebar to pause and continue. Press esc to stop.